SCHEMBL4196491

SCHEMBL4196491

CC(C)(C)OC(=O)N1CCC[C@@H](CC(=O)N2CC[CH]CC2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
KMT2A Q03164 1/20 0.50
FNTA P49354 1/20 0.49
FNTB P49356 1/20 0.49
GLS O94925 2/20 0.48
BACE1 P56817 2/20 0.45
ACKR3 P25106 1/20 0.45
CTSD P07339 1/20 0.45
USP30 Q70CQ3 1/20 0.44
KDM1A O60341 1/20 0.43
FEN1 P39748 1/20 0.43
SCN9A Q15858 1/20 0.43
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
HPGD P15428 1/20 0.42
HTR6 P50406 3/20 0.41
ITGB1 P05556 1/20 0.41
ITGA4 P13612 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4203164 1.00 MEN1 (0.50) MEN1ALDH1A1MAPTKMT2AFNTA
SCHEMBL4203171 1.00 MEN1 (0.50) MEN1ALDH1A1MAPTKMT2AFNTA
SCHEMBL4206186 0.93 MEN1 (0.48) MEN1ALDH1A1MAPTKMT2AFNTA
SCHEMBL4195107 0.93 MEN1 (0.48) MEN1ALDH1A1MAPTKMT2AFNTA
SCHEMBL4195100 0.93 MEN1 (0.48) MEN1ALDH1A1MAPTKMT2AFNTA
SCHEMBL4195097 0.84 KDM4E (0.48) MAPTFNTAFNTBGLSDDB1
SCHEMBL1225792 0.81 GLS (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL2461387 0.81 GLS (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL1225791 0.81 GLS (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL7014630 0.81 GLS (0.54) MEN1ALDH1A1MAPTKMT2AFNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275567-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2009-11-05 US disclosed
CN-101500569-A HIF hydroxylase inhibitors for treatment of anemia of cancer FIBROGEN INC (US) 2009-08-05 CN disclosed
CN-101490041-A 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation ASTRAZENECA AB (SE) 2009-07-22 CN disclosed
EP-2032559-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION AstraZeneca AB (SE) 2009-03-11 EP disclosed
WO-2007138268-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275567-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION CCNI, MKI67, CDK2 MEN1 1172/4885ALDH1A1 537/4885MAPT 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.